U.S. patent approval for Intervacc’s vaccine against infections caused by Streptococcus suis
Stockholm, November 22, 2023 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine against Streptococcus suis infections in pigs. The U.S. Patent No. 11,814,415 relates to a vaccine based on recombinant fusion proteins where patent protection is effective until 2037.
Streptococcus suis (S. suis) is an endemic cause of disease that results in significant economic losses to the pig industry throughout the world. The bacterium is transmitted from sows to piglets in the early days of life. Piglets develop disease post-weaning at between 4 and 10 weeks of age as the levels of maternal antibodies wane. Clinical signs include meningitis, arthritis, endocarditis and septicaemia leading to the death of many affected animals. The control of disease caused by S. suis currently requires the extensive use of antimicrobial agents, including penicillin. S. suis is also an important cause of zoonotic disease in humans. Therefore, the development of a safe and effective vaccine that protects piglets is an urgent unmet need.
“We reported previously proof-of-concept studies that showed our fusion protein vaccine prototype against Streptococcus suis was administered safely to pregnant sows and provided significant levels of protection to their piglets against an experimental challenge with S. suis at both four and seven weeks of age” explained Intervacc’s Chief Scientific Officer Dr. Andrew Waller. “The successful granting of this patent follows on from our earlier granted patent No. 11,155,585 and further strengthens Intervacc’s position in this important area of vaccine development”.
“There are approximately 10 million breeding sows in Europe, and we estimate that a vaccine against S. suis that is based on sows being in a vaccination schedule with a booster before each farrowing has a total accessible market value of approx. SEK one billion in Europe alone” said Intervacc’s CEO Jonas Sohlman. “We continue to progress our S. suis vaccine from the pre-clinical developmental phase towards pivotal clinical trials. The granting of this new patent highlights the potential of our technology platform to reduce the impact of bacterial infections and improve global food security for the benefit of both animal and human health”.
For more information please contact:
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.se
The information was submitted for publication, through the agency of the contact person set out above on November 22, 2023, 6.15 p.m. CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10
